Harmony Biosciences reaffirms 2026 net revenue outlook of $1 billion-$1.04 billion - HRMY News | RalliesHarmony Biosciences reaffirms 2026 net revenue outlook of $1 billion-$1.04 billion
H
HRMY• 2026 revenue outlook reaffirmed
- Harmony Biosciences reaffirmed full-year 2026 WAKIX net product revenue guidance of $1 billion to $1.04 billion.
- The outlook is supported by preliminary second-quarter WAKIX net revenue of about $261 million, up 30% year over year.
- Second-quarter revenue rose 21% from the first quarter, extending momentum through the first half of 2026.
